Welcome to our dedicated page for Codexis news (Ticker: CDXS), a resource for investors and traders seeking the latest updates and insights on Codexis stock.
Codexis, Inc. (Symbol: CDXS) is a pioneering leader in protein engineering, pushing the boundaries of biotechnology through its innovative approaches. Established in 2002, Codexis specializes in the rapid development and production of highly optimized proteins using its proprietary CodeEvolver® technology platform. This platform leverages the power of artificial intelligence and advanced high-throughput screening systems to efficiently introduce function-driven mutations, creating proteins meticulously tailored to meet specific performance requirements.
Codexis offers a broad spectrum of enzyme optimization services and biocatalyst products. These include biocatalysts and enzymes, which play crucial roles in various industries, including pharmaceuticals, food, and biofuels. The company's enzyme solutions are designed to improve the efficiency, cost-effectiveness, and environmental sustainability of production processes.
A significant portion of Codexis’ revenue is derived from product sales, while licensing its technology platform to pharmaceutical companies also contributes to its financial health. These partnerships enable pharmaceutical giants to harness Codexis’ technology in-house, facilitating the engineering of custom enzymes for their specific needs.
Codexis has a global revenue footprint, with contributions from the United States, Ireland, Switzerland, China, and other international markets. The company's innovative efforts have led to several strategic partnerships and collaborations, further cementing its position in the biotechnology sector.
Recent achievements include a strategic collaboration geared towards enhancing RNA therapeutic development, aimed at providing GMP-grade Codexis enzymes. Another notable development is the collaboration with TnX transposase, focusing on enhancing genomic applications.
Codexis continues to advance in the field of biotherapeutics, retaining economic interest while minimizing development and commercialization costs. The company remains committed to optimizing yield, purity, and quality in its offerings, ensuring that customers receive superior siRNA materials for preclinical testing.
For more information, Codexis frequently participates in industry conferences, presenting breakthrough research and advancements. Stay updated with the latest developments and announcements by following Codexis on various platforms.
Codexis, Inc. (NASDAQ: CDXS) has appointed Dr. Stephen Dilly as the new President and CEO, effective August 9, 2022. Dilly, a Codexis Board member and former CEO of Sierra Oncology, succeeds John Nicols, who is retiring after a decade of transformative leadership. Nicols will continue on the Board until June 2023 while transitioning to a Strategic Advisor role. Dr. Dilly brings over 30 years of experience in biopharmaceuticals, having previously led successful companies and developed numerous marketed drugs. Codexis aims to leverage its CodeEvolver platform for continued growth in enzyme engineering.
Codexis (NASDAQ: CDXS) has announced a multi-year agreement with Pfizer for supplying a high-performance enzyme crucial for producing nirmatrelvir, an active pharmaceutical ingredient in PAXLOVID™, which treats COVID-19. This partnership underscores Codexis’ rapid manufacturing capabilities and supports Pfizer's efforts to ensure the availability of this oral treatment globally. The agreement highlights Codexis’ role in advancing synthetic biology and improving pharmaceutical production efficiency.
Codexis (NASDAQ: CDXS) reported preliminary revenue results for Q2 2022, expecting approximately $38 million. Updated full-year revenue guidance is now projected between $135 million and $141 million. Product revenues from Pfizer are anticipated to reach the low end of $75 million to $80 million. The company notes a mix of fewer new deals and lower revenue from existing customers as reasons for the revised guidance. A detailed financial report will be released on August 4, 2022.
Codexis (NASDAQ: CDXS) has collaborated with Merck to publish a research paper in Science journal, focusing on enzyme engineering for site-selective synthesis of insulin bioconjugates. This partnership has led to significant innovations in the biotech field. Utilizing Codexis’ proprietary CodeEvolver® technology, the research outlines the development of specialized enzymes that enhance the precision of peptide modification, potentially creating new clinical leads. This collaboration underscores the promise of synthetic biology in improving therapeutic options.
Codexis, a leader in enzyme engineering, announced participation in three investor conferences. The events include the 19th Annual Craig-Hallum Institutional Investor Conference on June 1, 2022, the Benchmark Healthcare House Call Virtual 1x1 Investor Conference on June 2, 2022, and the Jefferies Healthcare Conference on June 9, 2022, where a fireside chat will be held. Investors can access a live webcast of the Jefferies event on Codexis' website, with a replay available for 90 days.
Codexis focuses on developing high-performance enzymes for various applications, including pharmaceuticals and gene therapies.
Codexis, a leader in enzyme engineering, announced participation in two investor conferences. Management will attend the UBS Global Healthcare Conference on May 23, 2022 for an in-person chat at 4:15 p.m. ET in New York. Additionally, they will participate in the H.C. Wainwright Global Investment Conference on May 24, 2022 at 7:00 a.m. ET, delivering a virtual presentation. Webcasts of both events will be available on the company's Investor Relations website for 30 days following the presentations.
Codexis (CDXS) announced presentations at the ASGCT Annual Meeting from May 16-19, 2022, showcasing results from three gene therapy programs. Utilizing the CodeEvolver® platform, the research highlights engineered enzymes for Hemophilia A, Fabry Disease, and Pompe Disease, demonstrating enhanced therapeutic efficacy. Key findings include engineered FVIII-BDD variants retaining over 80% activity after four days, and GLA variants achieving up to 20 times increased activity, potentially leading to improved patient outcomes and addressing unmet medical needs.
Codexis, Inc. (CDXS) reported Q1 2022 total revenue of $35.3 million, a 96% increase from $18.0 million in Q1 2021, with product revenue soaring by 200% to $30.7 million.
The gross margin expanded to 72%, largely due to higher margin product sales, primarily from CDX-616 used in Pfizer’s PAXLOVID™. The company reiterated its 2022 guidance for total revenues between $152 million and $158 million, with a projected growth of nearly 50%.
Codexis, a leader in enzyme engineering, announced two poster presentations at the American Society of Gene and Cell Therapy 25th Annual Meeting, scheduled for May 16-19, 2022. The presentations focus on enhancing treatments for Hemophilia A and lysosomal storage diseases using directed evolution.
Dr. Marcus Rohovie will present on improving Hemophilia A treatments, while Dr. Rachel C. Botham will address lysosomal storage disease therapies. Details and abstracts will be available on both the ASGCT website and Codexis’ website starting May 16.
Codexis, a prominent enzyme engineering company, will announce its Q1 2022 financial results on May 5, 2022. The report follows the market's close, and management will host a conference call at 4:30 p.m. ET to discuss results and provide a business update. Investors can access the live webcast on the Codexis Investor Relations website or participate via phone. Codexis leverages its CodeEvolver® platform to create high-performance enzymes for pharmaceuticals and biotherapeutics, aiming to enhance sustainability in manufacturing.
FAQ
What is the current stock price of Codexis (CDXS)?
What is the market cap of Codexis (CDXS)?
What does Codexis, Inc. specialize in?
How does Codexis generate revenue?
What industries benefit from Codexis’ products and services?
What is the CodeEvolver® technology platform?
Where does Codexis derive its revenue from geographically?
What recent collaborations has Codexis entered into?
What is the significance of Codexis’ strategic collaborations?
What recent achievements has Codexis made in biotherapeutics?
How does Codexis ensure the quality of its products?
How can I stay updated with Codexis’ latest news and developments?
